[Use of dopamine agonists in the treatment of Parkinson's disease].
Gekht
A B
AB
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D052160:Benzothiazoles; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000077465:Cabergoline; D018849:Controlled Clinical Trials as Topic; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010891:Piribedil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010919:Placebos; D000077487:Pramipexole; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D004873:Ergolines; D007211:Indoles; D010919:Placebos; D017366:Serotonin Receptor Agonists; D013844:Thiazoles; C046649:ropinirole; D010479:Pergolide; D001971:Bromocriptine; D000077487:Pramipexole; D010891:Piribedil; D008090:Lisuride; D000077465:Cabergoline